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ABSTRACT  
Urinary tract infections caused by multidrug resistant Gram negative bacilli constitute a major global healthcare problem. 
Fosfomycin is considered the best treatment option for such infections. Urine samples were collected and cultured in a tertiary 
care hospital (Urology). Identification of these uropathogens and their antibiotic sensitivity screening were performed 
according to CLSI guidelines. Urine samples (n=436) were selected in which Ps. aeruginosa and Acinetobacter baumannii were 
found to be the significant pathogens and treated-exposed to fosfomycin. Sixty six (15%) were identified as Acinetobacter 
baumannii, Ps. aeruginosa n=370(85%). Forty four percent of all Ps. aeruginosa were found to be multidrug resistant while 48.5% 
of the Acinetobacter baumannii strains were found multidrug resistant. Polymyxin B was found to be the most effective drug 
(100%) against all uropathogens and fosfomycin was found effective against 73% of the multidrug resistant Acinetobacter 
baumannii isolates and 70% of the multidrug resistant Pseudomonas aeruginosa strains. It may be concluded that antimicrobial 
activity (in vitro) of fosfomycin, especially against MDR uropathogens, is very effective. 
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RESUME  
Les infections des voies urinaires causées par les bacilles de multi résistants Gram négatifs, constituent un problème majeur de 
sante mondiale. Fosfomycine est considéré comme la meilleure option de traitement pour telles infections. Les échantillons 
d’urine ont été recueillis et cultives dans un hôpital de soins tertiaires. Identification de ces uropathogènes et programmation de 
leur sensibilité aux antibiotiques ont été réalisés selon les directives (CLSI). Les échantillons d’urine (n = 436) ont été choisis 
dans laquelle Ps. aeruginosa et Acinetobacter baumannii se sont trouves être l’agent pathogène important et traités – exposés a 
Fosfomycine. Soixante – six (15%) ont été identifies comme Acinetobacter baumannii, Ps. aeruginosa  = 370 (85%). Quarante – 
quatre pourcent de tous les Ps. aeruginosa se sont trouvés être multi résistants et  48,5% des souches Acinetobacter baumannii se 
sont trouves multi résistants. Polymyxine B a été trouvé d’être le médicament le plus efficace (100%) contre tous les 
uropathogènes et Fosfomycine a été trouvé efficace contre 73% des isolats de multi résistants Acinetobacter baumannii et  70% 
des souches de multi résistants Pseudomonas aeruginosa. On peut  conclure que l’activité antimicrobienne (in vitro) de 
Fosfomycine est très efficace, particulièrement contre les uropathogenes MDR. 
Mots – clés : Fosfomycine, les bacilles de Multi résistants Gram négatifs, les infections des voies urinaires, Ps. aeruginosa, 
Acinetobacter baumannii. 
INTRODUCTION 
Urinary infections (UTIs) due to multi-drug resistant 
Gram-negative bacilli (MDR-GNB) are an increasing 
clinical problem worldwide (1, 2). The prevalence of 
multi-drug resistant (MDR) bacterial species of 
Pseudomonas aeruginosa and Acinetobacter baumannii 
has increased considerably since the introduction 
followed by arbitrary use of new generation extended 




spectrum antibiotics like third and fourth generation 
cephalosporins, carbapenems, monobactams, broad 
and extended spectrum penicillins etc (3). During the 
last few years these organisms are undergoing genetic 
modifications and result in highly resistant forms that 
cause untreatable nosocomial infections and 
healthcare associated complications (4, 5). These 
bacterial strains create very serious problems for 
antibiotic treatment especially in critically ill patients 
admitted in intensive care units. Fosfomycin can be a 
potentially useful agent for urinary tract sepsis 
(caused by MDR-GNB), as many such strains remain 
susceptible to this decades old drug (6, 7). It is for this 
reason and along with its soft administration that it 
has been widely recommended and used for the 
treatment of uncomplicated urinary tract infections 
(8). It is a well-tolerated drug and has a broad 
spectrum of activity (9). The objective of this study is 
to manifest fosfomycin bioactivity against multi drug 
resistant Pseudomonas aeruginosa and Acinetobacter 
baumannii strains encountered in urinary tract 
infections. 
 
MATERIALS AND METHODS 
Collection sites (anatomical) of the urine samples 
Urine samples were collected from patients showing 
overt symptoms of urinary tract infections (UTIs) in a 
tertiary care hospital (Urology). A variety of 
collections were done including Foleys catheter 
collection, Midstream sample collection, Left and 
Right Percutaneous nephrostomy (L-PCN and R-
PCN) collection and Suprapubic (S/P) collection 
depending on the patient’s condition (10).  
Inoculation of urine samples 
All urine samples were inoculated on Cystine lactose 
electrolyte deficient (CLED) agar medium plates by 
1µl calibrated loops (Culti loops). Plates were 
incubated under aerobic conditions at 37oC for 24 
hours when colonies were observed for significant 
count and lactose or non lactose fermentative activity 
(10). 
Identification of uropathogens 
Significant counts (100 colonies) were counted on 
CLED medium plate i.e. equal to 105cfu/ml.  Gram 
staining was performed as preliminary step.  
Pathogens were identified by standard biochemical 
reactions or by automated profile index (API 20 NE) 
system (bioMerieux) where needed (10, 11). In this 
study 436 urine samples (Positive for Ps. aeruginosa 
and Acinetobacter baumannii) were selected for 
fosfomycin bioactivity. 
Antibiotic sensitivity screening and media 
Antibiotic sensitivity testing was performed by Kirby- 
Bauer disc diffusion method on Muller Hinton agar 
(Oxoid, UK) according to Clinical laboratory standard 
institute (CLSI) and European committee on 
antimicrobial susceptibility testing (EUCAST) (12, 13).  
Amikacin (AK30µg), Ampicillin (AMP10µg), 
Amoxicillin-clavulanic acid (AMC20/10µg), 
Aztreonam (ATM30µg), Ceftazidime (CAZ30µg), 
Cefoperazone-sulbactam (SCF105µg), Cefotaxime 
(CTX30µg), Ciprofloxacin (CIP5µg), Fosfomycin 
(FOS300µg), Imipenem (IPM10µg), Nalidixic acid 
(NA30µg), Nitrofurantoin (F300µg), Pipracillin-
tazobactam (TZP100/10µg), Polymyxin B(PB300µg) 
and Trimethoprim / sulfamethoxazole   
(SXT1.25/23.75µg) discs were used. All the antibiotic 
discs were obtained from Oxoid.   MacFarland 0.5 
suspension of the isolate was made in normal saline 
that was spread by swab over the Muller Hinton 
(MH) agar and appropriate discs of the above 
indicated antibiotics were placed at the 15 mm 
distance from each other. Quality control strains E.coli 
ATCC25922 and Pseudomonas aeruginosa ATCC27853 




 In this study 436 urine samples (Positive for Ps. 
aeruginosa and Acinetobacter baumannii) were selected 
for fosfomycin bioactivity. Out of the isolated 
bacterial strains, a total of n=66(15%) were identified 
as Acinetobacter baumannii and n=370(85%) as Ps. 
aeruginosa. Antibiogram for Acinetobacter baumannii is 
shown in fig-1 and fig-2 depicts the antibiogram for 
Ps. aeruginosa. Data was interpreted in percent by 




Key: (S)= Sensitive, (R)= Resistant  
The expansions of all the antibiotics abbreviations are 
given in materials and methods section. A total of 
44% of Ps. aeruginosa isolates were 
multidrug resistant while 48.5% of all
TABLE: 1 ANTIBIOTIC SENSITIVITY PATTERNS OF MULTI
BAUMANNII AND PS. AERUGINOSA
 
Antibiotics  Acinetobacter baumannii
   (MDR) 48.5% 
Percentage (%) 
   to individual drug
Amikacin   33 
Ampicillin   0 
Amoxicillin-clavulanic acid  11 
Aztreonam   14 
Cefotaxime    8 
Ceftazidime   - 
Ciprofloxacin   11 
Fosfomycin   73 
Imipenem   42 
Nalidixic acid   8 
Nitrofurantoin   5.5 
Polymyxin B   100 
Cefoperazone-sulbactam  - 









































































found to be 
 Acinetobacter 
baumannii isolates were also 
resistant. Results of antibiogram and bioactivity of 
fosfomycin against the MDR isolates are presented in 
table.1. 
-DRUG RESISTANT (MDR) 
. 
  Ps. aeruginosa 
  (MDR) 44% 
of resistant strains Percentage (%) of resistant strains 
   to individual drug   
   38   
   - 
   - 
   49 
   - 
   2 
   1   
   70 
   6 
   - 
   - 
   100 
   2 
   8 


















































































































The present study was conducted to evaluate the 
potential of the older antibiotic (fosfomycin) for the 
treatment of UTIs, especially against MDR-GNB 
pathogens. Prevalence of MDR Acinetobacter 
baumannii (48.5%) and Ps. aeruginosa (44%) in patients 
of UTI was observed. These findings are on higher 
side than the previous reports regarding prevalence 
of MDR-GNB in Karachi (14) which points to an 
increase in the drug resistance. 
The current study demonstrates the resistance of 
Acinetobacter baumannii and Ps aeruginosa to 
therapeutically important antibiotics. Interestingly, 
higher frequency of resistance was noticed in 
Acinetobacter baumannii as compared to Ps. aeruginosa. 
Compared to other antibiotics, Polymyxin B (100%), 
Fosfomycin (82%), Imipenem (69%), Pipracillin-
tazobactam (62%) and Amikacin (60%) were found to 
be effective (bioactive) against all the isolates of 
Acinetobacter baumannii (fig.1). For MDR Acinetobacter 
baumannii, many antibiotics showed a decrease in 
susceptibility (< 50% sensitive) but interestingly, 
Polymyxin B and Fosfomycin were found bioactive 
(100%) and (73%) of these isolates, respectively (table 
1). For all the isolates of Ps. aeruginosa, most effective 
antibiotics included: Polymyxin B (100%), Aztreonam 
(76%), Amikacin (63%) and Fosfomycin (85%) 
respectively (fig.2). For MDR Ps. aeruginosa, all 
antibiotics showed decreased bioactivity except 
Polymyxin B (100%) and Fosfomycin (70%) which 
showed more bioactivity against these isolates. Very 
important antibiotics like Amikacin, Amoxicillin-
clavulanic acid, Cefotaxime, Ciprofloxacin, Imipenem, 
Cefoperazone-sulbactam and Pipracillin-tazobactam 
were found to show decreased bioactivity against 
both MDR-GNB types (with some variations). 
However, Polymyxin B has come out to be the most 
effective against both MDR-GNB type of the isolated 
strains but this antibiotic leaves behind many side-
effects as well. So, Fosfomycin should be the better 
choice for MDR-GNB and it has another merit (can be 
used orally as well as intravenously). In fact, 
Fosfomycin has emerged as a promising treatment 
option. It has rare adverse reactions which may 
develop in 1-8% of all the patients, the most common 
ones being diarrhea, nausea, vomiting, skin rashes, 
heartburn, vaginitis, headache, chills and asthenia 
(15). Fosfomycin has a low molecular weight with a 
relatively long half‑life post intake (mean half life-SD, 
5.7-2.8 h) and therefore, penetrates various tissues 
with ease, achieving the minimum inhibitory 
concentrations needed to inhibit the growth of most 
of the pathogens (16). Resistance emergence rate is 
low and most frequently acquired by chromosomal 
mutations that do not spread easily (17).  
In previous studies, around 10% of strains of Ps. 
aeruginosa were found resistant to fosfomycin (18). 
Current studies on Ps. aeruginosa isolates 
demonstrated similar rates of resistance to fosfomycin 
in vitro (19), and this study correlates with these 
findings. Polymyxin B and colistin also demonstrated 
good results against Ps. aeruginosa and Acinetobacter 
baumannii. Keeping this in view, further trials can be 
done for combined therapy (Fosfomycin with colistin 
or Polymyxin B). Further studies to be based on 
molecular mode of action of fosfomycin are needed. 
Fosfomycin appears to be picked as an excellent 
therapeutic choice for the treatment of both MDR-
GNB pathogen types. 
 
CONCLUSIONS 
Fosfomycin is a bactericidal agent that encounters a 
low level of resistance as compared to other 
antibiotics. Antimicrobial activity of fosfomycin, 
especially against MDR uropathogens, makes it an 
effective and safe drug for the treatment of UTIs 
caused by Gram‑negative bacteria, especially against 
the MDR Acinetobacter baumannii and Ps. aeruginosa 
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